Dementia is a complex process involving an interplay between specific molecular pathways affecting cellular functions, leading to loss of synaptic connections, cell death, gliosis 1 , inflammation, and disruption of functional networks underlying cognition, personality, behaviour and sensorimotor functions, eventually attacking an individual's autonomy 2 . Ageing is the most robust risk factor for dementia, with more than 90% of dementias presenting after the age of 65 years. With an increase in the mean age of the population, the incidence and prevalence of dementia continue to steadily increase worldwide. In 2015, the World Alzheimer Report 3 , a comprehensive meta-analysis of population-based studies, estimated that 46.8 million people worldwide are living with dementia, and that number is expected to reach 131.5 million by 2050. In the USA alone, an intervention delaying onset of dementia by 5 years would reduce Medicare costs by US$283 billion in 2050 (REF. 4).
. Ageing is the most robust risk factor for dementia, with more than 90% of dementias presenting after the age of 65 years. With an increase in the mean age of the population, the incidence and prevalence of dementia continue to steadily increase worldwide. In 2015, the World Alzheimer Report 3 , a comprehensive meta-analysis of population-based studies, estimated that 46.8 million people worldwide are living with dementia, and that number is expected to reach 131.5 million by 2050. In the USA alone, an intervention delaying onset of dementia by 5 years would reduce Medicare costs by US$283 billion in 2050 (REF. 4 ).
Historically, definitions of dementia have been weighted toward prominent deficits in memory, as observed in typical amnestic Alzheimer disease (AD) 5 . The definition was revised in 2011 to reflect the plethora of cognitive and behavioural changes that can cause decline from baseline levels of functioning 6 . The revised definition requires impairments in at least two neuropsychiatric or cognitive domains that are not better explained by nondegenerative or primary psychiatric disorders, or systemic conditions such as delirium. The diagnostic process requires a history taken from the patient and a reliable informant, as well as objective measures of impairment through a neuropsychiatric and neuropsychological assessment 6 . Definitive classification of dementia is based on the underlying neuropathology, as noted on autopsy orin rare cases -biopsy. However, with various degrees of certainty, dementias can be sorted into syndromic categories on the basis of distinct clinical features, evolution over time (symptomatic progression), and other ancillary diagnostic information. Different pathologies can cause similar clinical syndromes, although rigorous syndromic classification can often predict the underlying pathology. The accuracy of clinicopathological diagnoses is improved by the use of imaging, biofluid and genetic biomarkers. In addition, simple treatable causes of cognitive impairment, such as hypothyroidism, vitamin B 12 deficiency, infection or medication-induced problems, must be sought and ruled out.
In this Review, we highlight key elements that distinguish the most common dementia subtypes. We offer an overview of dementia classification and diagnosis, with an emphasis on salient clinical features, neuropathology, relevant epidemiology, risk factors, and in vivo biomarkers. We conclude with a summary of where the field stands with regards to the diagnostic process, and where it is heading.
. The vast majority of non-vascular dementias fall into six main categories of neurodegenerative proteinopathy: amyloid-β (Aβ), microtubuleassociated protein tau, TAR DNA-binding protein 43 (TDP-43), fused in sarcoma (FUS), α-synuclein, and prion protein (FIG. 1) . Often, the presence of proteinopathies precedes clinical deficits by years. Whether these proteins are simply biomarkers reflecting the toxic molecular milieu, active agents of toxicity, or a combination of the two is open to debate.
The prion protein propagates along neuronal networks and can seed healthy cells 8, 9 . Evidence emerging in recent years suggests that other neurodegenerative proteinopathies -in particular, tau and α-synucleinshare similar mechanisms of propagation [10] [11] [12] [13] . Indeed, pathological and in vivo functional studies indicate that the majority of neurodegenerative diseases begin focally in a subset of vulnerable neurons or glia, with subsequent spread throughout the brain along specific paths 7, 14 . Moreover, rather than being a homogeneous disease process, dementias seem to constitute a continuum of pathophysiological change, in turn giving rise to a spectrum of symptoms of varying severity. Therefore, definitions of the underlying pathologies, incorporating information from in vivo biomarkers of disease, are changing to reflect asymptomatic (or presymptomatic) and symptomatic phases of disease, also referred to as preclinical and clinical, respectively.
Three dichotomous clinical categories -early versus late, gradual versus rapid, and sporadic versus familial -apply distinctly or in combination to the spectrum of dementing processes. The age cut-off for early versus late onset of dementia is arbitrarily set at 65 years, which is historically the typical age for retirement. However, the incidence of many pathologies increases with age, frequently resulting in coexistence of more than one pathology (mixed pathology), which blurs syndromic delineations in the latter decades of life 15 . Dementia epidemiology remains challenging: the accuracy of incidence and prevalence estimates is hampered by diagnostic challenges, and the absence of pathological confirmation in most of the published literature 16 . Globally, AD accounts for approximately 60% of all dementias 17, 18 . However, when dementias are subdivided into early versus late, frontotemporal dementia (FTD) seems to be at least equally prevalent to AD before the age of 65 years [19] [20] [21] [22] [23] . Many patients diagnosed with AD also show multiple non-AD pathologies involving tau, TDP-43 and α-synuclein 24, 25 . Sex differences between syndromes are observed, with over-representation of AD in females after age 75 years 26 . Survival after diagnosis ranges from months to decades. Regardless of the disease specificity, as dementia progresses, vegetative functions eventually become affected, with death frequently ensuing from swallowing difficulties, falls and infections.
It should be noted that established diagnostic criteria are primarily aimed at homogenizing clinical research cohorts, although they also have value for the clinician in establishing certainty around a specific diagnosis. In clinical practice, every patient presents with a unique story of decline. The work of the clinician lies in translating the patient's story into a dynamic neuroanatomical map of the underlying pathology and its associated proteinopathy, supported by in vivo biomarkers of disease.
Alzheimer disease
Pathology: a dual proteinopathy AD pathology is a dual proteinopathy defined by the coexistence of extracellular aggregates of Aβ 42 fibrilsand, to a lesser extent, Aβ 40 fibrils -that form neuritic Aβ plaques (hereafter referred to as amyloid), and intracellular aggregates of hyperphosphorylated tau (P-tau), termed neurofibrillary tangles (NFTs) 27, 28 . The gradual spread of NFTs (Braak stages I-VI) 29 correlates better with progression of cognitive deficits 30, 31 than does amyloid deposition 32 , which is often diffuse at the time of symptom presentation 33, 34 . The order in which these proteinopathies develop, and their potentially synergistic relationship with neurodegeneration, continue to be investigated. In sporadic AD, both proteinopathies precede symptom onset by years 31 . In an autopsy series of 2,332 brains 35 , Braak and colleagues found NFTs in the absence of amyloid in the early stages of AD. By contrast, with the exception of one individual with an autosomal dominant genetic cause of amyloidopathy (amyloid precursor protein (APP) gene triplication in Down syndrome), the researchers did not detect amyloid plaques in the absence of NFTs. The observation of tau pathology early in the disease course and its close association with the severity of neurodegeneration has prompted reconsideration of AD as a tau opathy. Nevertheless, by definition, AD-related dementia remains a dual proteinopathy with postulated synergy between tau and amyloid in the progression toward dementia.
From an anatomical standpoint, the abnormal intracellular aggregation of tau may begin subcortically in noradrenergic projection neurons of the locus coeruleus [36] [37] [38] [39] , extending along functional networks
Key points
• Definite classification of dementia is based on the underlying neuropathology • Accumulation of abnormally folded proteins lies at the heart of dementia neuropathology • Alzheimer disease pathology can give rise to subtypes with focal onset in functional networks outside the memory system, such as language, visuospatial and behavioural executive domains • Frontotemporal lobar degeneration, associated with aggregates of tau, TDP-43 or FUS, can give rise to three core frontotemporal dementia syndromes and three associated syndromes • Clinical classification of dementia syndromes is based on diagnostic criteria that rely heavily on the specificity of affected domains and the evolution of deficits in these domains • In vivo biomarkers of disease include imaging findings of morphological, molecular and functional changes, both upstream and downstream of the disease processes subserving the limbic system. Noradrenergic deficiency, and ensuing symptoms such as attentional deficits, are intimately connected to the neuroanatomical substrates of AD. In addition, involvement of cholinergic neurons in the nucleus basalis of Meynert results in an important cholinergic deficit, and loss of serotonergic neurons in the dorsal raphe nucleus is thought to contribute to psychiatric changes. The first cortical regions displaying accumulation of abnormal tau include the transentorhinal cortex of the medial temporal lobes, the hippocampal formation and the basal forebrain, followed by the allocortex and the rest of the neocortex. From a molecular standpoint, abnormally phosphorylated tau no longer binds to microtubules, leading to misfolding and aggregation, forming 'pretangles' that gradually fill affected neurons. Pretangles transform into insoluble fibrillary and argyrophilic neuropil threads, and eventually NFTs. In addition, tau is extensively involved in neuronal signalling pathways, which become affected with disease progression. Affected cells survive for years, eventually undergoing premature apoptosis, which results in loss of grey matter and symptomatic progression. With increasing age, other co-pathologies, such as vascular disease and Lewy body disease (LBD), are found post mortem 24 . Additional dimensions to AD proteinopathies continue to be uncovered. For instance, several structurally diverse molecular subtypes of Aβ fibrils that have differential associations with AD subtypes (phenotypes) have been reported [40] [41] [42] [43] . 
Lewy bodies
Normal proteins
Misfolded and/or aggregated proteins , and α-synuclein. These normal proteins misfold and/or accumulate in intracellular or extracellular compartments in specific areas of the CNS. Four major pathological disease categories are recognized: prion disease, Alzheimer disease (AD), frontotemporal lobar degeneration (FTLD) and Lewy body diseases (LBD). The pathologies can involve multiple molecules; for example, AD is a dual proteinopathy with Aβ and tau aggregates. Also, in some cases of prion disease, Aβ in seen in addition to the principal aggregates of misfolded scrapie prion protein (PrP Sc ). The majority of FTLD cases are associated with three different proteinopathies: tau, TDP-43 and FUS. Each pathological entity can in turn manifest as a variety of clinical syndromes, sometimes featuring symptoms that bridge syndromes. Asterisks indicate frontotemporal dementia (FTD) syndromes that, in addition to FTLD, can be associated with AD neuropathology. Genetic pleiotropy is also at play: mutations in certain genes -for example, GRN -have full penetrance for one pathology (FTLD-TDP) and associated FTD syndromes, while representing a risk factor for another pathology (AD). In addition, certain fully penetrant genetic mutations (for example, VCP mutations), are associated with additional systemic disease manifestations. The rich and diverse clinical expression of neurodegenerative processes is best illustrated in FTLD, a pathological category with six distinct clinical syndromes. Of note, FUS pathology causing FTLD is typically not associated with FUS mutations, which more often cause amyotrophic lateral sclerosis. Aβ, amyloid-β; CJD, Creutzfeldt-Jakob disease; FTD-MND, FTD with motor neuron disease; PPA, primary progressive aphasia.
PrP
The current model of AD is based on distinct but related pathological and clinical continua. AD pathology progresses through disease states, with spread of NFTs, neurodegeneration, and phases of amyloid. These states are reflected in progression of clinical symptoms 44 , from prodromal AD or mild cognitive impairment (MCI) 45, 46 to mild, moderate or severe dementia 6 .
Risk factors
In autosomal dominant AD (ADAD), mutations in known disease-related genes, including APP, presenilin-1 (PSEN1) and presenilin-2 (PSEN2), contribute directly to increased Aβ 42 production, amyloid formation and inflammation [47] [48] [49] . Sporadic AD is a genetically complex disease, for which the strongest monogenic risk factor remains the apolipoprotein E ε4 allele (APOE*ε4): homozygosity for this allele increases the odds of AD 15-fold, compared with threefold in heterozygotes 50 . Genome-wide association studies have identified over 20 risk and protective genetic variants, with modest individual effect sizes 51 . Recent work using genotype data from over 70,000 patients with AD and age-matched controls has shown that a polygenic hazard score composed of AD-associated risk genotypes and APOE status can predict the age-specific risk of developing AD 52 . Additional risk factors for AD include age, family history of AD, cerebrovascular disease (CVD) and its associ ated risk factors (including hypertension and diabetes), chronic inflammation, obstructive sleep apnoea, traumatic brain injury (TBI), and low education 53, 54 . In fact, emerging data-driven models suggest that vascular disease and dysregulated inflammation are early risk factors in the pathophysiological cascade leading to AD 55 . The mechanisms of vascular diseaseespecially small vessel disease (SVD) -and AD-related neurodegeneration might be intricately interrelated 56 .
Biomarkers
The most commonly used in vivo biomarkers of AD neuro pathology are cerebrospinal fluid (CSF) levels of Aβ 42 , tau and P-tau (BOX 1; TABLE 1). Decreases in CSF Aβ 42 can be observed in the early stages of disease, before overt neurodegeneration occurs, and can precede increases in CSF tau and P-tau by years 30 , or even decades in the case of ADAD 49 . Of the various biomarker combinations under investigation, the Aβ 42 :Aβ 40 ratio shows the best correlation with amyloid deposition at the MCI stage, and the highest diagnostic accuracy for AD versus other dementias 57 . AD states can only be determined with certainty post mortem, although advances in structural and molecular neuroimaging are making ante-mortem determination a possibility [58] [59] [60] . Several tau PET ligands show promise, with tracer uptake matching the predicted topographic Braak staging of NFTs in AD [61] [62] [63] [64] . However, only amyloid PET, using the F-FDG-PET are topographical methods of assessing neurodegeneration and neuronal dysfunction (for example, synaptic loss), respectively. Antecedent to atrophy, hypometabolism characteristically involves the medial temporal and medial parietal (precuneus) lobes, posterior cingulate cortex, and temporo parietal association cortices 66 . In typical, amnestic AD, atrophy is first noted in the medial temporal lobes, gradually involving the broader temporoparietal cortices with disease progression 67 (FIG. 2) .
From a clinical perspective, biomarkers should be used to confer confidence on the clinical diagnosis or to determine disease state, with their interpretation being contingent on clinical phenotype. Biomarkers diminish in utility with age, as the incidence of asymptomatic AD neuropathology increases dramatically from 70 years of 
Phonemic paraphasias
Errors in speech resulting in substitution of parts of the intended word by other phonemes, leading to generation of a -sometimes non-existent -word sounding similar to the target word (for example, pipe for pile, loan for moan, or papple for apple).
Visual agnosia
Inability to recognize or interpret visual stimuli despite intact vision.
Alexia
Inability to read, which comprises inability to read out loud and/or comprehend.
Ideomotor apraxia
Deficit in the ability to voluntarily plan or complete a motor task, with preservation of involuntary (automatic) motor planning when the subject is cued. This preserved ability to perform automated motoric responses to cuing contrasts with 'ideational apraxia', in which the ability to select the appropriate motor programme or sequencial steps, even in the presence of cuing, is lost.
Prosopagnosia
Inability to recognize faces, also known as 'face blindness' .
age. Consequently, they are most useful in diagnosing early-onset AD (EOAD), or in the presence of atypical features, such as rapid rate of progression, prominent behavioural symptoms, or motor dysfunction. In late-onset AD (LOAD), structural neuroimaging (MRI or CT) remains useful in determining contributing factors, such as vascular disease, and assessing the presence of alternative pathologies such as strokes or malignancies. From a research perspective, the combination of tau with amyloid PET 60 offers the possibility of ante-mortem disease state determination, and clarification of the temporospatial relationship between the proteinopathies as individuals transition into the symptomatic stage of disease. However, in-depth clinical phenotyping and assessment of functional status continue to serve as gauges of disease progression.
Biomarker findings can conflict with the clinical picture: even a 'typical' progressive amnestic AD phenotype can be associated with negative amyloid biomarkers. Combined with an atypical pattern of atrophy or hypometabolism, and possibly increased CSF tau levels, negative amyloid biomarkers can be suggestive of other neurodegenerative diseases, such as FTD with TDP-43 neuropathology (see below), argyrophilic grain disease, LBD, or tangle-only dementia 68 .
Clinical syndromes
A diagnosis of AD dementia requires insidious onset and gradual progression of deficits in two cognitive domains, one being memory. These original diagnostic criteria have been revised to incorporate in vivo biomarkers of the disease process as well as genetics. The new criteria 6 distinguish between levels of certitude, with probable and possible AD categories, as well as probable or possible AD with in vivo evidence of the AD pathophysiological process or genetic risk factors.
AD clinical diagnoses can be sporadic (the majority of cases) or familial. Sporadic AD is predominantly a late-onset dementia, presenting after the sixth to seventh decade of life, whereas familial AD usually presents earlier. Among individuals affected by AD, an estimated 1-5% present with EOAD 69 . EOAD is genetically complex, and only an estimated 10-20% of individuals with this condition have a clear family history showing a Mendelian inheritance pattern. The genes most commonly implicated in EOAD are PSEN1, PSEN2 and APP.
A few syndromes that classically present early are discussed below. However, presentation of early EOAD as a whole and the spectrum of ADAD syndromes is a vast topic, outside the scope of this Review, and the interested reader is directed to previously published work 70, 71 . Typical Alzheimer disease. Sporadic LOAD is the prototypical AD syndrome. Amnestic MCI, defined as isolated difficulties with formation of new episodic memories, with preserved functional independence 46 , is frequently the first clinical presentation of typical -or amnestic -AD 6 . Decreased semantic fluency can also be noted on neuropsychological testing. Overall, typical AD is defined by prominent early episodic memory deficits, reflecting neurodegeneration of the limbic system and the medial temporal lobe. Additional deficits such as acalculia and visuospatial dysfunction localize to parietal lobes (FIG. 2) . Noradrenergic and cholinergic deficits can be prominent, affecting mood and frontal lobe functions, with diminished attention and concentration. Early and prominent involvement of cognitive domains other than memory is suggestive of atypical or variant AD, detailed below.
Atypical or variant Alzheimer disease.
In variant AD, deficits in language, visual processing and executive and/or behavioural functions constitute the first presenting symptoms, and frequently overshadow milder disturbances in episodic memory in the initial stages of the disease. These focal cortical presentations occur with higher frequency in patients with EOAD 72 . The three well-described syndromes -logopenic variant primary progressive aphasia (lvPPA), posterior cortical atrophy (PCA), and behavioural dysexecutive AD -begin in the inferior parietal lobule or superior temporal gyrus, the occipitoparietal lobes, and the fronto parietal neuronal networks, where peak atrophy can be seen.
As lvPPA is an aphasia syndrome, the earliest and most debilitating symptom must be impairment in language, even in the presence of other deficits, including episodic memory [73] [74] [75] . Frequently, patients present with anomia due to single-word retrieval difficulties, with frequent pauses and hesitations in spontaneous speech, and loss of fluency (Supplementary information S1 (box)). As patients attempt to circumvent word-retrieval blocks through simplifications, substitutions and circumlocutions, use of indefinite or demonstrative pronouns and unspecified nouns such as 'stuff ' increase with greater imprecision in language. Limitation in auditory working memory can lead to difficulties in repetition and comprehension of long sentences. Phonemic paraphasias also occur.
At onset of lvPPA, routine 'small talk' may sound normal, with deficits becoming apparent when access to infrequently used words is sought. With disease progression, patients develop features common to other aphasias, as well as verbal episodic memory deficits, typical of limbic AD. Concordant presence of atrophy (FIG. 2) and hypoperfusion or hypometabolism in the posterior perisylvian region and/or parietal lobe on MRI, single-photon emission CT (SPECT) and PET supports this diagnosis 66, 67 . In addition, AD biomarkers (CSF or PET) have high utility for increasing confidence in the diagnosis, as well as for distinguishing lvPPA from FTD language syndromes that are much less frequently caused by AD pathology 76 (see FTD section below). PCA, historically referred to as visual AD 77, 78 , involves a plethora of signs and symptoms that reflect degeneration of the occipitoparietal and sometimes the posterior temporal lobes (FIG. 2) . Deficits include higher-order visual processing impairments, such as visual agnosia, dressing apraxia, alexia, elements of Balint and Gerstmann syndromes, ideomotor apraxia, and prosopagnosia. Some patients experience visual field cuts early in the disease course, and many eventually become cortically blind. By contrast, memory and verbal fluency impairments are typically more modest. The preservation of insight in the setting of severe impairments can contribute to depression. Topographic changes in the posterior cortex, noted on ancillary testing, are supportive of the diagnosis 72, 79 . PCA and dementia with Lewy bodies (DLB) both target posterior cortical regions and, therefore, share noted changes in higher-order visual processing. However, these conditions differ with regard to typical age of onset and other specific core and supportive diagnostic criteria. On average, symptom onset for PCA is in the fifth or sixth decade of life -earlier than for DLB, which is typically a late-onset dementia. AD is the most common pathology associated with PCA, although cases with Lewy bodies, prions or primary tau pathology have been reported.
The behavioural dysexecutive variant of AD 80 , also referred to as frontal variant AD, can present with predominance of behavioural and/or executive dysfunction [81] [82] [83] [84] [85] . In the behavioural subtype, voxel-based morphometric studies reveal temporoparietal atrophy with relative preservation of frontal grey matter (FIG. 2) . Consequently, Rabinovici and colleagues have favoured the use of the term behavioural dysexecutive variant, rather than frontal variant 80 . The behavioural variant can easily be mistaken for possible behavioural variant FTD (bvFTD, see below); however, it is characterized by a more dampened and restricted behavioural disturbance. Although memory deficits can lag behind behavioural dysfunction, they still tend to occur earlier than in sporadic bvFTD 80 . In the University of California, San Francisco (UCSF) series, amyloid PET and postmortem evaluations indicated a rate of 10-40% for the misdiagnosis of behavioural variant AD as bvFTD [86] [87] [88] .
Aut o s o m al d o mi n ant Al z h e i m e r d i s e a s e .
Overproduction of amyloid, caused by mutations in APP, PSEN1 or PSEN2, is thought to be an important aspect of ADAD pathophysiology. This phenomenon is intricately linked to certain complications that are prevalent in ADAD, including cerebral amyloid angiopathy, and the related microbleeds, progressive white matter disease and microinfarcts. Although non-cognitive mani festations of disease affect only a fraction of individuals with ADAD 70 , they occur with higher frequency than in sporadic EOAD 71 . Besides early age of onset 64 , profound amnesia and a family history, certain features, such as psychiatric symptoms (including hallucinations and delusions), parkinsonism, gait abnormality, pseudobulbar affect and early prominent myoclonus, have been reported in mutation carriers 71, 89 . Overall, the reported ADAD phenotypes are highly variable, possibly owing to other genetic modifiers that influence the molecular effects of mutated gene products. . In contrast with other neurodegenerative diseases, vascular cognitive impairment (VCI) and vascular dementia (VaD) 91, 92 are not characterized neuropathologically by accumulation of abnormal proteins. Nonetheless, vascular disease tends to be progressive and degenerative, with cognitive impairment following clinical stroke or resulting from subclinical vascular brain injury 93 . The Newcastle pathological categorization distinguishes six vascular injury subtypes that can cause a dementia syndrome 94 . Chronic cerebral SVD, the most insidious subtype, shows the strongest association with cognitive impairment. From a microstructural perspective, SVD is associated with blood-brain barrier (BBB) compromise, resulting in leakage of fluid and macromolecules, and chronic white matter disease 95, 96 . SVD can cause cortical and subcortical microinfarcts, lacunar strokes, a chronic state of cerebral hypoperfusion, hippocampal atrophy, and sclerosis. Interestingly, SVD is also an important risk factor for large vessel disease 97 . The histopathological substrate of SVD includes lipohyalinization of vessels, formation of microatheromas within vessels, fibroid necrosis, enlarged Virchow-Robin spaces (eVRS), pallor of perivascular myelin, and astrocytic gliosis 98 . In addition to age-related and possibly synergistic interactions between SVD and AD pathology, cerebral amyloid angiopathy can cause a vigorous inflammatory and non-inflammatory SVD, with microbleeds and infarcts.
Risk factors for poststroke dementia 99 , which include age, low education, female sex, vascular risk factors, and global and medial temporal lobar atrophy on structural imaging, overlap extensively with those identified for AD, suggesting possible mechanistic interactions and cumulative risk of these two pathologies. Hereditary vascular disease syndromes such as CADASIL are associated with specific patterns of change, as well as a more aggressive disease process. In general, the spatial variability in manifestation of vascular disease echoes the principle of selective vulnerability seen in neurodegenerative diseases with underlying proteinopathy. The extent of overlap between molecular mechanisms of sporadic and genetic disease remains to be determined.
Population-based clinicopathological studies have yielded prevalence estimates of 2.4-23.7% for pure VaD and 4.1-21.6% for mixed AD and VaD 100, 101 . A large number of dementia patients with prominent CVD show multiple pathologies, most frequently including AD and LBD 102 . The variability in types and location of vascular disease, existence of mixed pathology, and lack of inter nationally accepted consensus criteria for VaD neuropathology might explain the limited sensitivity and specificity of ante-mortem clinical diagnostic criteria, and the variability in prevalence estimates reported in autopsy series 92 . Nevertheless, the consistent decrease in pure VaD and the related increase in mixed pathologies with age are well established, and imply intricate relationships between vascular disease, cerebral ageing and accumulation of abnormal proteins in neurodegeneration 99, 103 .
Clinical syndromes and biomarkers
The VCI-VaD spectrum encompasses a heterogeneous group of clinical presentations. Numerous diagnostic criteria have been drafted for sporadic VaD to date. The modified Hachinski Ischemic Scale (HIS), which includes 13 features aimed at obtaining a global ischaemic score, can be easily applied in clinical practice 104 . The HIS was specifically designed to enhance the distinction between VaD and AD 105 . The scoring system includes risk factors such as history of hypertension, as well as symptoms of small and large vessel disease that localize to white and grey matter, such as stepwise cognitive decline, abrupt onset, a history of stroke, focal neurological signs and symptoms, emotional lability, and somatic complaints. The criteria are limited by lack of integration of neuroimaging information, but the sensitivity (70%) and specificity (80%) for separating VaD from AD remain acceptable.
The most widely used criteria in VaD clinical trials research were formulated by the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) 106 . Emphasis was placed on neuroimaging evidence of disease in key areas involved in VaD (frontal, temporal or parietal cortices, thalamus, and basal ganglia), and visual quantification of abnormal white matter signal. In 2014, the International Society of Vascular Behavioural and Cognitive Disorders (VASCOG) drafted a new set of criteria addressing the breadth of symptoms, high variability in severity of deficits and rate of progression, and frequent occurrence of mixed CVD and AD pathologies 107 . Early changes at the prodromal VCI stage include deficits in cognitive flexibility and verbal memory retrieval 108 .
As the frontal white matter is particularly vulnerable to SVD 56 , typical cognitive deficits with disease progression include executive dysfunction, with diminished attention and concentration and impaired spontaneous retrieval of stored memory. Behavioural changes such as irritability are common, and parkinsonism ( frequently symmetrical) can also be noted.
Vascular disease is necessary but not sufficient for the development of VaD. Biomarker predictors of clinical deficits include the volume and pattern of white matter disease, as well as the patient's cognitive reserve 109 . White matter disease, microbleeds and eVRS all constitute imaging biomarkers of SVD 110 . In research, new imaging techniques, including diffusion tensor imaging (DTI), proton magnetic resonance spectroscopy and dynamic contrast-enhanced MRI, are being used to quantify white matter disease and BBB disruption. In addition, CSF and peripheral biomarkers of inflammation and BBB dysfunction show promise for improving the diagnosis of SVD and VaD 109, 111 .
Frontotemporal dementia
Pathology: tau, TDP-43 and FUS FTD syndromes arise from frontotemporal lobar degeneration (FTLD), a gross pathological term denoting the degeneration of cortical and subcortical structures within frontal and temporal regions of the brain. Affected structures include the frontoinsular cortices, anterior temporal poles, basal ganglia, brainstem and thalamus, as well as the cerebellum in certain genetic forms of the disease. Gradually, neuronal networks that subserve personality, behaviour, executive functions, language and motor abilities are disrupted, with relative sparing of memory and visuospatial functions 112, 113 . FTLD and the clinical syndromes of FTD have diverse molecular pathologies, risk factors and genetic foundations.
Most FTLD cases (90-95%) are FTLD-tau or FTLD-TDP, caused by intracellular aggregates of tau or TDP-43, respectively [114] [115] [116] [117] 
. Most of the remaining 5-10% of cases are FTLD-FUS, caused by intracellular FUS inclusions 118, 119 
. Alternative splicing of microtubule-associated protein tau (MAPT) premRNA gives rise to tau isoforms containing three or four microtubule-binding domain repeats (3R and 4R). Therefore, FTLD-tau is further subdivided into 3R, 4R and 3R/4R tauopathies. Pick disease is a 3R tauopathy, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are 4R tauopathies, and AD is a mixed 3R/4R tauopathy. Mixed FTLD pathologies and unclassifiable tauopathies are also encountered.
Each FTLD pathological subtype can cause several FTD syndromes (FIG. 3) . There are three core FTD syndromes, including the most common -behavioural variant FTD (bvFTD) -and two language syndromes, namely, nonfluent/agrammatic variant PPA (nfvPPA) and semantic variant PPA (svPPA) 120 . In addition, three
Box 2 | FTLD proteinopathies

Frontotemporal lobar degeneration (FTLD) is caused predominantly by intracellular aggregates of tau, TAR DNA-binding protein 43 (TDP-43) or fused in sarcoma (FUS).
Tau
Tau is encoded by the microtubule-associated protein tau (MAPT) gene. Alternative splicing of MAPT mRNA leads to production of six tau isoforms with differential expression across the brain. Tau binds to and stabilizes microtubules, which are important for cellular morphology and function. In neurodegenerative disorders, the normally phosphorylated tau becomes aberrantly hyperphosphorylated, dissociates from microtubules, and forms aggregates within neurons and glia. MAPT mutations mainly cause FTLD-tau pathology, giving rise to syndromes such as nonfluent/agrammatic variant primary progressive aphasia. Patients with frontotemporal dementia (FTD) syndromes who harbour MAPT mutations tend to be relatively young (<50 years), present with disinhibition rather than apathy, display ritualistic behaviour, and develop features of semantic impairment.
TDP-43
TAR DNA-binding protein 43 (TDP-43) is encoded by the TARDBP gene. TARDBP mutations typically cause amyotrophic lateral sclerosis (ALS), but are also, in rare cases, implicated in FTLD-TDP types A-D and U. TDP-43 pathology is subclassified according to patterns of TDP-43-containing neuronal cytoplasmic inclusions and dystrophic neurites in diseased neurons. All FTD syndromes except for progressive supranuclear palsy syndrome can be caused by FTLD-TDP. The TDP-43 C-terminus has been shown to contain a prion-like domain that permits formation of TDP-43 oligomers, and is a hotspot of disease-causing mutations in ALS.
FUS
Fused in sarcoma (FUS) is an RNA-binding protein involved in splicing and nuclear export of mRNA. FTLD-FUS has three subtypes: atypical FTLD with ubiquinated inclusions, basophilic inclusion body disease, and neuronal intermediate filament inclusion disease. FUS mutations are mainly associated with ALS, but can give rise to behavioural variant FTD, FTD with motor neuron disease, or language FTD phenotypes. A specific phenotype related to sporadic FTLD-FUS pathology has emerged, with young onset (22-46 years), prominent caudate atrophy, and unique phenotypic features of marked obsessiveness, social withdrawal, hyperorality (often with pica), and stimulus-bound and repetitive, ritualistic behaviours. The cognitive profile consists of subcortical executive dysfunction in the absence of cortical language, perceptual and praxis impairments.
FTD motor syndromes are recognized: FTD with motor neuron disease (FTD-MND), and two variants with parkinsonism, namely, corticobasal syndrome (CBS), and PSP syndrome (PSP-S) (FIG. 1) .
The heterogeneity in clinical presentations of FTLD molecular pathologies renders ante-mortem patho logical predictions difficult. In familial FTLD, however, the affected genes are associated with homogenous pathological signatures. Mutations in the C9orf72, progranulin (GRN), valosin-containing protein (VCP) and TDP-43 (TARDBP) genes are associated with TDP-43 pathology, whereas MAPT mutations are consistently associated with tau pathology
. In addition, a few nonfamilial clinical syndromes have homogenous pathological substrates. Approximately 90% of individuals with svPPA have FTLD-TDP type C pathology, and SteeleRichardson-Olszewski syndrome (PSP-RS) is linked to 4R tau pathology (FIG. 3) . FTD-MND is almost always associated with TDP-43 pathology (usually type B), and around 85% of all nfvPPA cases show either 4R (CBD or PSP) or 3R tau pathology. By contrast, all molecular subtypes are seen with bvFTD: at UCSF, 60% of cases show TDP-43 aggregates, 30% show some form of tau pathology, and 10% show FUS neuropathology (D. C. Perry et al., unpublished observations).
Approximately one-third of patients with FTD have a family history of dementia, although the proportion varies between FTD subtypes. Investigation of familial FTD has revealed notable variability in penetrance of mutations and associated phenotypes, including age of onset and rate of progression 121 . FTD-MND is the most heritable subtype, and svPPA -notwithstanding a few cases associated with GRN mutations -is the least heritable [122] [123] [124] [125] [126] .
Expansion of an intronic hexanucleotide repeat in
C9orf72 is the most common hereditary cause of FTLD-TDP 127 , as well as the most frequent genetic aetiology of familial and sporadic amyotrophic lateral sclerosis (ALS)
. TANK-binding kinase 1 (TBK1) mutations have also been reported to cause FTD-MND spectrum disorders 128 . GRN mutations cause about 25% of familial cases of FTLD-TDP 129 , and typically give rise to a bvFTD syndrome or, less commonly, CBS, language or mixed behavioural-language FTD 130, 131 . TARDBP mutations are responsible for 4% of familial ALS cases reported, and only rarely cause FTD. VCP mutations can cause FTLD pathology with a syndrome including hereditary inclusion body myopathy and Paget disease of bone 132, 133 . The MAPT H1 haplotype is a genetic risk factor for PSP and CBD 134 .
Clinical syndromes and biomarkers FTLD molecular pathologies give rise to degeneration in vulnerable neuronal networks subserving cognitive, behavioural and sensorimotor functions. Psychiatric symptoms such as depression occur with varying frequency across different FTD subtypes 135 . Early in the clinical course, self-awareness and insight commonly diminish, so despite disabling deficits affecting social and interpersonal relationships, patients report depression less frequently than in other dementia syndromes. However, important behavioural and personality changes contribute to a high caregiver burden 136 . Each FTD syndrome is characterized by a chronology of deficits partially dictated by the underlying proteinopathy 7 . In bvFTD and right-sided svPPA (svPPA-R), global hemispheric differences, with right-predominant patterns of atrophy, lead to striking behavioural symptoms, whereas patients with left-predominant atrophy, such as nfvPPA and svPPA-L, tend to present with languagerelated deficits (FIG. 4) . Consequently, prototypical findings on formal neuropsychological evaluation vary depending on the syndrome, stage of disease, and individual factors, such as baseline cognitive function, or disease resilience 137 . However, deficits in executive function -possibly including face and emotion recognition -and changes in language, with relative preservation of episodic memory and visuospatial functions, can generally be noted. With disease progression, the mesiotemporal and parietal lobes also become involved, with corresponding impairment in episodic memory and visuospatial functions.
The reported age of FTD onset ranges from the 20s to the 90s, with most patients presenting between 45 and 65 years of age. Motor FTD syndromes can present later, with mean age of onset in the seventh decade of life 120, 138, 139 .
Behavioural variant frontotemporal dementia. The earliest symptoms of bvFTD include progressive changes in emotion, personality and behaviour, especially relating to interpersonal interactions and social Nature Reviews | Neurology 
Anticipation
Genetic phenomenon relating to the gradual expansion of a mutation with each generation, usually resulting in earlier age of onset and more-severe symptoms when passed on to the next generation.
conduct, localizing to disrupted paralimbic networks including the anterior cingulate, insular, medial frontal and orbitofrontal cortices 140 . Dysfunction of the dorsolateral prefrontal cortices contributes to impairment in executive functions. Most patients present with early changes in empathy; apathy or inertia; disinhibition; stereotypic behaviour; alteration in food preference and eating behaviour; and dysexecutive symptoms 113, 141 (Supplementary information S1 (box)). Among these early symptoms, loss of empathy seems to have special diagnostic value, but is challenging to ascertain in practice. In relation to disinhibition and loss of insight, transgression of social and moral rules is common, giving rise to criminal and sociopathic behaviour 142 . Memory and visuospatial deficits are unusual early in the illness, although a subset of patients exhibit early problems with episodic memory. An amnestic phenotype is more frequently observed in individuals harbouring expansions in C9orf72 (REF. 143 ). The underlying neuropathology in amnestic FTD is thought to be TDP-43-related hippocampal disease and sclerosis 144 . The differential diagnosis in such cases includes typical LOAD or mixed pathology. Amyloid biomarkers can be helpful in cases of pure FTLD-related hippocampal disease.
Patients with bvFTD frequently present with psychiatric symptoms, at onset or during the course of their illness. Distinguishing behavioural features from primary psychiatric disorders, such as depression, border line personality disorder, bipolar disorder and schizophrenia, can be challenging 145, 146 In a large case series including 751 individuals with bvFTD, 6% of patients presented with psychosis early in their disease course 146 . Approximately 20% of patients have delusions and 10% have hallucinations. These symptoms are more common in genetic cases caused by mutations in C9orf72 (REF. 147) (BOX 3) and GRN. Mania has also been reported 148 . Using voxel-based morphometry, Rosen and colleagues demonstrated that core neuropsychiatric symptoms of bvFTD, such as apathy, disinhibition, eating disorders and aberrant motor behaviour, localized to right frontal structures (FIG. 4) . Severity of symptoms correlated with extent of atrophy in the right-hemispheric anterior cingulate cortex, ventromedial superior frontal gyrus, posterior ventromedial prefrontal cortex, lateral middle frontal gyrus, caudate head, orbitofrontal cortex, and anterior insula 149 . In addition to psychiatric symptoms, parkinsonism with axial rigidity often emerges in bvFTD.
Progression of symptoms, and neurodegeneration demonstrated by atrophy on MRI, provide important clues for the differential diagnosis of bvFTD. The diagnostic criteria were revised in 2011 to incorporate the extended spectrum of psychiatric and motor symptomatology, as well as topographical biomarkers of disease 113 (TABLE 1) . Currently, the pattern of neurodegeneration seen on structural MRI constitutes the most helpful biomarker of disease (FIG. 4) . However, hypoperfusion on SPECT and hypometabolism on 18 F-FDG-PET precede atrophy, and have potential utility early in the disease before overt neurodegeneration. When the differential diagnosis includes the behavioural variant of AD, AD biomarkers can be helpful, as dual pathology is uncommon in early-onset dementias.
The clinical phenotype of bvFTD is influenced by the underlying molecular pathology. For instance, in comparison with bvFTD patients who have Pick disease, those with CBD pathology tend to have more dorsal than ventral frontal atrophy, and relative preservation of the frontoinsular rim. Consequently, executive dysfunction and anxiety are more prominent than disinhibition, emotional dysregulation, social misconduct and changes in eating behaviour 150 . bvFTD associated with C9orf72 expansion also has distinct clinical features and patterns of neurodegeneration 151 
A subgroup of patients meet the core diagnostic criteria for bvFTD at presentation, but show little or no symptom progression, and have -at most -modest atrophy on brain MRI. The neurodegenerative basis of this 'phenocopy' syndrome has been debated. Some individuals with bvFTD phenocopies carry C9orf72 expansions 152 . Moreover, a slowly progressing subgroup with predominant subcortical atrophy and FTLD-TDP pathology was recently identified, almost one-quarter of whom had mutations in FTD-related genes 153 .
Language-centred frontotemporal dementias. The language-centred FTDs generally show focal onset but, with disease progression, deficits eventually arise in all language functions. Therefore, the different subtypes are distinguished by the chronology and severity of deficits in specific linguistic functions. Neurodegenerative diseases targeting the language circuitry often present asymmetrically, with dominant (frequently left) hemispheric disease manifesting as language syndromes [154] [155] [156] (FIG. 4) .
Patients with nfvPPA present with fluency impairment and/or agrammatism, and most eventually develop both features. These deficits localize to the disrupted frontoinsular language network, with atrophy noted
Box 3 | C9orf72
Intronic hexanucleotide (GGGGCC) repeat expansions in C9orf72 are the most common genetic cause of familial and sporadic frontotemporal dementia (FTD) plus or minus motor neuron disease (MND) 127 , with a suspected single-founder effect in Northern Europe 256 . Molecular pathologies, in descending frequency, include TAR DNA-binding protein 43 (TDP-43) type B, TDP-43 type A and corticobasal degeneration (rare). Common syndromes (with or without MND) in descending frequency include behavioural variant FTD, mixed behavioural and semantic language deficits, nonfluent/agrammatic variant primary progressive aphasia, and behavioural and nonfluent language symptoms 257 . Symptoms more frequently observed in mutation carriers in comparison to individuals with sporadic FTD 147, 257 include greater disinhibition and less apathy; psychosis (~30%); paranoia and delusional and/or irrational thoughts (~25%), such as somatoform delusions of infestation (<4% of nongenetic FTD cases); complex repetitive delusion-related behaviours (as opposed to simple motor stereotypies); and amnesia, with or without TDP-43-related hippocampal sclerosis 144, 145 . In fact, progressive amnesia can cause misdiagnosis as 'atypical' early-onset Alzheimer disease. Concomitance of FTD and amyotrophic lateral sclerosis in C9orf72 carriers can be associated with prominent bulbar dysfunction. Atrophy on MRI is variable and can be modest in comparison to the severity of clinical deficits. In addition to the frontotemporal lobes, cerebellar, parietal and thalamic atrophy can be noted 158 . White matter atrophy has been reported at preclinical stages. Variability in penetrance, clinical features and age of onset is suggestive of potential anticipation mechanisms and modifying factors (including epigenetic factors and other genes). For a more detailed review on C9orf72, see Yokoyama et al. 121 .
Surface dyslexia and dysgraphia
Impairment in the ability to read and write words that are considered 'irregular' with regard to their spelling-to-sound correspondence (for example, friend, island or yacht), as opposed to 'regular' words (for example, fire, lemon or computer). This impairment can result in regularization errors, that is, words are erroneously spelled according to the regular phonetic rules.
Associative agnosia
Impaired recognition of visually presented objects despite intact visual perception of these objects. Also known as 'visual object agnosia' .
Hypergraphia
Compulsive and overwhelming urge to write, with potential intraindividual variability in style and content during the disease course. most frequently in the left inferior frontal and insular cortices 157 (FIG. 4) . Speech becomes nonfluent, gradually more telegraphic and less melodic (aprosodic). Apraxia emerges, with inconsistent sound errors and distortions, especially with pronunciation of consonant clusters, as well as effortful, halting speech with groping of the tongue and lips (Supplementary information S1 (box)). Deficits in grammar, which can be first noted in writing, eventually limit comprehension, especially of the passive voice or complex syntax. Anomia is not a central deficit, but delayed naming, with hesitations, and word-finding pauses are frequently noted. Repetition is less impaired than spontaneous speech, and semantic language typically remains preserved well into the disease process. Progressive deficits resemble the lesion-based model of Broca aphasia. Motor deficits, including asymmetric parkinsonism and/or pyramidal signs, occur in most patients, even early in the illness.
Differentiating nfvPPA from lvPPA can be challenging, with commonalities including preserved object meaning in the presence of progressive anomia and loss of fluency. In such instances, AD biomarkers such as CSF analyses or amyloid PET can be helpful; in comparison with lvPPA, only a small fraction of nfvPPA cases are caused by AD pathology. The diagnostic criteria for nfvPPA are supported by markers of neurodegeneration and neuronal dysfunction, as measured by MRI, PET or SPECT, in the left posterior frontoinsular region (TABLE 1) .
In svPPA, degeneration of the anterior temporal lobes (FIG. 4) disrupts access to semantic memory 75 . Anomia and single-word comprehension deficits, starting with low-frequency items, are essential for diagnosis 158 . Difficulties in confrontation naming are present in other language-dominant neurodegenerative diseases, but are most severe in semantic variants (Supplementary information S1 (box)). Critically, the loss of semantic knowledge in svPPA encompasses all sensory modalities, including visual, tactile, olfactory and gustatory, in addition to auditory. Moreover, the deficits extend to reading and writing, with the emergence of surface dyslexia and dysgraphia 75 . Although motor speech production and grammar are initially unaffected, communication becomes gradually more difficult, with impoverishment of content and increasingly vague speech. Among all the FTD syndomes, svPPA is associated with the longest survival times.
In addition to prosopagnosia and associative agnosia, right anterior temporal variants of svPPA (svPPA-R) present with prominent behavioural and personality changes that frequently overshadow more-subtle linguistic deficits 159, 160 . Compulsions, loss of empathy with ensuing 'coldness' , and child-like behaviour can be observed. A decline in semantic knowledge regarding people familiar to the patient, graded by frequency of interactions with those people, has been reported 161 . Affected individuals can also display features of Geschwind syndrome 162 , including rigidity in philosophical beliefs or religious dogmatism, hypergraphia, hyposexuality, and a tendency to inappropriately prolong conversations, termed 'viscosity' (REF. 159 ). Selective tissue loss in the anterior temporal lobes can help distinguish svPPA-R from bvFTD. The svPPA-R variant presents an exception to the coherence of the current PPA nosology, as the development of language deficits is delayed until the pathology extends into the dominant hemisphere 159, 163 . The neuropathological substrate of svPPA is almost always TDP-43 type C The images show the patterns of atrophy observed on structural imaging in various frontotemporal dementia (FTD) syndromes, which arise from frontotemporal lobar degeneration. The core neuropsychiatric symptoms of behavioural variant FTD (bvFTD), such as apathy, disinhibition, eating disorders and aberrant motor behaviour, localize to right frontal structures. Patients with nonfluent/agrammatic variant primary progressive aphasia (nfvPPA) present with fluency impairment and/or agrammatism. These deficits localize to the frontoinsular language network, with atrophy noted most frequently in the left inferior frontal and insular cortices (the entire network is not depicted on this figure) . In semantic variant PPA (svPPA), degeneration of the anterior temporal lobes disrupts access to semantic memory.
presentations in which other pathological processes are suspected, AD biomarkers can diminish uncertainty regarding the underlying pathology. A mixed PPA bridging the two main FTD language phenotypes, characterized by concomitant onset and progression in agrammatism and semantic deficits, has also been described 165 . However, this condition is more frequently associated with AD 166 , although cases of tauopathy have also been reported 76 . Progressive deficits in language can arise as a secondary feature of other syndromes 167 , but such presentations do not meet the core PPA diagnostic criteria and cannot, therefore, be classified as PPA subtypes.
Motor frontotemporal dementias. The spectrum of FTD extends to syndromes with pyramidal and/or extrapyramidal impairments. These 'motor FTD syndromes' can present later than nonmotor syndromes, with mean age of onset in the seventh decade of life 120, 138, 139 . FTD and MND are increasingly perceived along a clinicopathological continuum with shared fundamental biology. ALS and FTD-MND are mostly associated with TDP-43 pathology, and FTD-MND is frequently caused by C9orf72 mutations
. Approximately 60% of patients with FTD have evidence of MND on electromyography, with 10-15% of patients developing clinical signs of MND 168, 169 . Conversely, around 50% of patients with MND develop cognitive decline without meeting the research diagnostic criteria for FTD 170 . The MND clinical phenotype is typically ALS, although upper motor neuron (primary lateral sclerosis) and lower motor neuron (progressive muscular atrophy) disorders have also been described 171 . Early bulbar dysfunction is observed more frequently in FTD-MND than in isolated ALS, and patients with FTD-MND show the shortest survival among individuals with FTD syndromes. The clinical course of FTD-MND can be very aggressive, with acceleration at the onset of MND.
PSP-S refers to a range of clinical syndromes that are mainly -but not exclusively -caused by 4R FTLD-tau pathology (FIG. 3) . Other than PSP pathology, PSP-S is associated with CBD and Pick disease. PSP-S can manifest with a combination of features, including atypical parkinsonism with axial, symmetrical rigidity; a stare with furrowing of the brow (procerus sign); supranuclear gaze palsy; and prominent frontal lobe dysfunction 172 (Supplementary information S1 (box)). Limited to no response to dopaminergic therapy is typical. PSP-S invariably involves atrophy of the midbrain tegmentum and the pons 173 , although the timing and, therefore, the symptomatic chronology varies across subtypes. The classic PSP-S presentation, PSP-RS, is characterized by early involvement of the midbrain with ensuing supranuclear gaze palsy, gait instability and falls. PSPparkinsonism and PSP-pure akinesia and gait freezing closely resemble PD 174 . Of these two conditions, PSPparkinsonism is the more responsive to dopaminergic medications. Psychiatric symptoms (depression and anxiety), and profound sleep disruption associated with hyperarousal often precede PSP-S and can remain prominent once the parkinsonian features emerge.
PSP-RS has the highest predictive value for underlying PSP pathology. Although saccade abnormalities, including increased latency, decreased velocity and decreased gains, are associated with numerous neurodegenerative pathologies, including CBD, Pick disease, and AD, patients with PSP-RS display the most severe visually guided saccade abnormalities 175 . Therefore, careful examination of eye movement abnormalities can be diagnostically valuable. Decreased vertical saccade velocity correlates with dorsal midbrain atrophy (TABLE 1) . Moreover, quantification of anteroposterior midbrain to pons ratio has high specificity for PSP pathology, and has potential diagnostic utility 176 . PSP-S due to PSP (4R FTLD-tau) pathology is associated with shorter survival.
CBD is another 4R FTLD-tau pathology, and is implicated in approximately 35% of cases of CBS. A UCSF study found that patients with pathologically proven CBD presented with bvFTD, nfvPPA or executive-motor syndrome with early extrapyramidal motor symptoms such as ridigity and akinesia 177 . CBS is a pathologically diverse syndrome that involves progressive neurodegeneration of dorsal posteromedial frontal, perirolandic and insular cortices. The syndrome typically includes motor, behavioural and cognitive changes 177 . Alien limb phenomena occur in a minority of cases, usually in the later stages 178 (Supplementary information S1 (box)). CBS, as defined by the diagnostic criteria, has low pathological predictive value 177, 178 . CBS can be associated with FTLD-tau (CBD, PSP or, less frequently, Pick disease), FTLD-TDP or AD pathology (FIG. 3) . Extension of atrophy into frontal cortices is suggestive of FTLD-tau pathology, whereas posterior extension into the precuneus and temporo parietal regions is predictive of CBS due to AD (CBS-AD). In addition, individuals with CBS-CBD display pronounced dorsal frontal atrophy, whereas patients with CBS-AD tend to have more posterior involvement (TABLE 1) . From a neuropsychological perspective, group comparisons demonstrate greater visuospatial and memory deficits, concordant with greater temporoparietal degeneration, in patients with CBS-AD in comparison with CBS associated with underlying FTLD 179 . The pathological heterogeneity of CBS limits its clinical and research utility. Diagnostic criteria for CBD syndromes, or clinical phenotypes predictive of possible or probable underlying CBD pathology, may be more useful 178 .
Lewy body dementia
Pathology: α-synucleinopathy Lewy body dementias include DLB and Parkinson disease (PD) dementia (PDD), which lie along a clinicopathological continuum defined by characteristic intracellular α-synuclein aggregates (Lewy bodies) that cause dysfunction of cerebral neuronal networks.
Traditionally, PD pathology is thought to originate in the caudal brainstem, typically involving the dorsal IX/X motor nucleus and the intermediate or magnocellular reticular zone of the caudal medulla, before extending, possibly transynaptically 180 , to the rostral brainstem -resulting in prodromal REM sleep behaviour dis order (RBD), mood disorders and anxiety -the substantia nigra and, eventually, the basal ganglia, and cortex 36, 181 . However, recent evidence suggests that the pathology actually originates in the enteric nervous system 182 , progressing to involve the CNS via the vagus nerve 183 . The pathological progression of DLB remains unclear.
DLB and PDD typically manifest symptomatically between the ages of 60 and 90 years. Most patients with DLB show mixed pathology, with concomitant presence of vascular disease and/or AD pathology [184] [185] [186] . Similarly, the cortical pathology observed in patients with PDD is often mixed 187, 188 , with coexisting AD pathology leading to more-advanced dementia 189 . Not surprisingly, the genetics of AD pathology and LBD overlap to some extent 190 : the APOE*ε4 genotype is overrepresented in sporadic LBD 191 , whereas the APOE*ε2 allele seems to be protective against DLB as well as sporadic AD 192 . Other genetic risks for LBD include mutations in SNCA and LRRK2 (REF. 193 ). Mutations in SCARB2 (REF. 194) and GBA specifically increase the risk of DLB, and result in younger age of onset 195 . Risk factors for DLB, other than genetic modifiers, remain to be discovered. Pesticide exposure, TBI and a history of melanoma are overrepresented in patients with PD, and are possible risk factors for PDD and DLB.
Clinical syndromes
The main difference between DLB and PDD hinges on the temporal relationship of cognitive decline and neuropsychiatric symptoms to parkinsonism, with the two conditions showing early and late onset of cognitive symptoms, respectively 196 . Original descriptions of PD emphasized an absence of cognitive deficits [197] [198] [199] ; however, recent observations support insidious spread of pathology along cognitive networks, with approximately one-fifth of patients diagnosed with at least MCI at the time of presentation 200 .
Dementia with Lewy bodies. The defining clinical features of DLB localize to cortical and subcortical structures, with the ensuing characteristic combination of cognitive and motor dysfunction 196 . The disease typically progresses slowly; however, a rapidly progressive dementia syndrome is also possible 201 . The core diagnostic features of DLB include fluctuating cognition, recurrent visual hallucinations, and parkinsonism. The fluctuations in mental status, conceived as a low-grade chronic delirium, may be due to profound cholin ergic deficits in addition to neocortical Lewy body pathology 202 . Visuospatial and constructional deficits are frequently seen in early AD, but are also suggestive of Lewy body pathology 203, 204 , where they foreshadow more-rapid decline and visual hallucinations 205 . In comparison with AD, however, memory functions are often preserved in the early stages of DLB, although episodic memory deficits are frequently reported with older age, possibly due to mixed Lewy body and AD pathology 24 . Other features include anxiety and depression 206 , autonomic symptoms 207 (including constipation and hypersialorrhea), olfactory dysfunction 208, 209 , and severe neuroleptic sensitivity, causing exacerbation of parkinsonism. RBD has great diagnostic utility due to its high positive predictive value (>80%) for α-synuclein-related neurodegeneration 210, 211 .
Parkinson disease dementia.
Most patients with PD develop MCI 212, 213 (labelled as MCI-PD) and can progress to dementia [214] [215] [216] [217] . Cognitive deficits are routinely missed in clinical practice, as motor symptoms are frequently the focus of diagnosis and treatment 218, 219 . Although patients with PDD primarily present with executive dysfunction, localizing to disrupted dorsolateral prefrontal-striatal networks 220 , the cognitive profile can be diverse 200 . The best predictors of further cognitive decline seem to be deficits in verbal and visual memory, semantic fluency, and visuospatial abilities 221 .
Biomarkers
18
F-FDG-PET typically reveals reduced metabolism and perfusion in occipital cortices in patients with DLB 222 , with additional involvement of frontal and parietal lobes noted in patients with PDD 223 (TABLE 1) . One distinguishing feature between DLB and AD is the relative sparing of the posterior cingulate cortex -the so-called posterior cingulate 'island sign' -in DLB 224 . Studies suggest that CSF markers can also help to distinguish these dementia syndromes from AD, with lower CSF α-synuclein levels being observed in patients with DLB 225 . By contrast, in vivo detection of amyloid pathology through CSF analysis or molecular imaging has not proven useful for distinguishing these diseases, owing to the frequent coexistence of AD and Lewy body pathology 226, 227 . Low dopamine transporter (DAT) uptake in the basal ganglia, as shown by SPECT or PET, is suggestive of DLB. An autopsy-based study that compared neuroimaging with clinical diagnosis alone showed that 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) SPECT dopaminergic imaging increased specificity and overall diagnostic accuracy 228 . Though clinically available, DAT scans are seldom necessary in the presence of supportive clinical features. Should ancillary studies be necessary, a characteristic marked reduction in tracer uptake is seen on myocardial 123 I-metaiodobenzylguanidine ( 123 I-MIBG) SPECT in patients with diffuse LBD. MRI has limited ability to discriminate between DLB and PDD, as atrophy can be modest and/or lack focality in the early stages of LBD.
Prion disease Pathology and risk factors
Prion diseases, also known as transmissible spongiform encephalopathies, are rapidly progressive neurodegenerative diseases caused by propagation of misfolded prion proteins in the nervous system 229 . A histopathological hallmark is the protease-resistant amyloid-containing prion protein, also known as scrapie prion protein (PrP Sc ). PrP Sc shows a high degree of β-pleated sheet structure, in contrast to PrP C , the nonpathogenic, mostly α-helical and protease-sensitive cellular isoform 230 . In the majority of cases, misfolding of this protein occurs spontaneously, possibly via de novo structural changes in the PrP gene PRNP. This subtype is referred to as sporadic CJD (sCJD) 231 . Less frequently, CJD cases are familial, exhibiting an autosomal dominant pattern of inheritance. Over 20 known causative mutations have been identified worldwide 232 . Familial cases of CJD are subdivided into three clinicopathologically distinct categories: familial CJD (fCJD), fatal familial insomnia (FFI) and Gerstmann-Straussler-Scheinker syndrome (GSS). In rare cases, prion disease is acquired, giving rise to variant CJD (vCJD). The majority of these cases (about 200) occurred in the UK and France in the past two decades, and were associated with consumption of cattle affected by bovine spongiform encephalopathy 233 . Finally, prion disease can be acquired iatrogenically via cadaveric transplants, human-derived hormones (growth hormone) or medical instrumentations 234 , or via cannibalism -a condition known as kuru, the historic disease of the Fore tribe in Papua New Guinea 235 . Importantly, the incubation period for acquired CJD can be several decades 232 . Astrocyte proliferation, gliosis, and neuronal loss are found in all prion diseases, but other histopathological features allow distinction between four major patho logical subtypes: diffuse spongiosis (or vacuolation, due to focal swelling of axonal and dendritic processes) of grey more than white matter neuropil, with minimal PrP-amyloid plaques, characteristic of sCJD and fCJD; 'florid' PrP-amyloid plaques surrounded by a vacuole or halo, characteristic of vCJD 232 ; multicentric PrP plaques extensively affecting the molecular layer of the cerebellum, pathognomonic of GSS; and focal and relatively isolated anterior and dorsomedial thalamic nuclear gliosis, as seen in FFI. In addition, some mutations leading to GSS were shown to be associated with cortical NFTs 236, 237 . The peak incidence of sCJD occurs between 55 and 75 years of age, whereas fCJD typically presents before age 55, and vCJD commonly occurs even younger, in the late teens or young adulthood 232 .
Clinical syndromes and biomarkers sCJD has a protean presentation, reflecting the variety of neuropathological subtypes 238 and the extent of the CNS territory affected. The condition most often presents with rapidly progressive dementia (mean disease duration 4.0-6.5 months), featuring behavioural abnormalities, cerebellar ataxia, pyramidal and/or extra pyramidal signs, and myoclonus as the disease progresses. The two main modes of onset are cognitive deficits (usually memory impairment, but sometimes also deficits in language, executive function or visual processing) and cerebellar ataxia, predominantly limiting gait 231 . These presentations are sometimes preceded by neuropsychiatric symptoms, such as agitation, aggressiveness, depression, apathy or anxiety, or vague constitutional symptoms, such as dizziness, fatigue or sleep disturbances [239] [240] [241] [242] . If not already present in the early stages of the disease, about half of patients with sCJD will develop behavioural changes, including psychiatric symptoms and higher cortical deficits, such as aphasia, neglect, acalculia, apraxia or astereognosis, followed in frequency by visual or oculomotor dysfunctions. Other deficits commonly affect motor (extrapyramidal, pyramidal) and sensory (pain, paraesthesia) functions. Depending on the initial presentation of the disease, sCJD can resemble other non-rapidly progressive neurodegenerative syndromes, such as the language forms of FTD, AD or CBS; however, the rapid emergence of new deficits often in a matter of days to weeks, as well as the pace of general decline, should raise concern for prion disease. The symptoms can occasionally progress more slowly: in one subtype of sCJD, mean disease duration is 17 months 243 . sCJD phenotypes are in part determined by a polymorphism at codon 129 (methionine or valine) in the PRNP gene and the pattern of PrP Sc cleavage by protease K, giving rise to six molecular subtypes -MM1, MV1, VV1, MM2, MV2 and VV2 (REFS 244, 245) . The MM2 molecular subtype is further divided into a thalamic and a cortical subtype on the basis of the distribution of pathology in the CNS. The most common subtypes, MM1 and MV1 (about 40% of cases), are pathologically and clinically identical and are, therefore, known as MM1/MV1. These subtypes are associated with more-rapid clinical progression than MV2. VV2, which presents with rapidly progressive ataxia, is another common subtype. The MM2-thalamic subtype has features of FFI, and is also referred to as sporadic fatal insomnia 232 .
Compared with most cases of sCJD, vCJD shows slightly slower progression (mean disease duration 14.5 months) 233 , with a prolonged prodromal phase typically dominated by psychiatric symptoms. At more-advanced stages, however, vCJD is clinically indistinguishable from sCJD. All but one of the reported cases of vCJD were homozygous for methionine (MM) at codon 129 (REF. 233 ).
fCJD may progress more slowly than its sporadic counterpart, but otherwise presents with similar clinical phenomenology. FFI and GSS have distinctive clinical features. The initial symptoms of FFI are severe insomnia followed by dysautonomia, with cognitive and motor dysfunctions typically lagging. GSS manifests as a slowly progressive dementia associated with cere bellar ataxia or a parkinsonian syndrome that commonly starts in the fifth decade of life; however, the age of onset, symptomatic progression, and disease duration vary greatly, even within a given family.
Routinely available ancillary diagnostic tests for CJD include EEG, MRI, and CSF biomarkers (BOX 1;  TABLE 1 ). In addition, because the lymphoreticular system is invaded in vCJD, tonsillar biopsy is considered to be a sensitive test for PrP Sc (REF. 246 ). EEG findings of frequent periodic sharp-wave complexes (1-2 Hz) with occasional triphasic morphology are supportive of a CJD diagnosis, but can manifest at a late stage 247 -if at all -so are of limited diagnostic utility.
Classic MRI findings in CJD include hyperintense signal along various segments of the cortical ribbon, as well as in the thalamus, on diffusion-weighted imaging, often corroborated by evidence of fluid restriction on apparent diffusion coefficient sequences. These findings have an
Astereognosis
Inability to recognize an object by active touch alone, in the absence of primary sensory deficit.
estimated diagnostic accuracy of 97% 248 . Symmetrical involvement of both pulvinar and medial thalami -the so-called 'double hockey stick sign' -is not specific for any particular form of CJD 249 ; however, involvement of the pulvinar nuclei alone is pathognomonic for vCJD.
Despite good sensitivity, CSF biomarkers show limited specificity in CJD 250 . A combination of elevated concentrations of 14-3-3, total tau, neuron-specific enolase and S100β increase the diagnostic accuracy, but remain inferior to MRI 251 . These tests are best used as a complement to neuroimaging, and in the work-up of the differential diagnosis 248, 252 . An emerging CSF realtime quaking-induced conversion (RT-QuIC) test shows high specificity (98.5%) and sensitivity (92%) 253 for the diagnosis of CJD, with close concordance between laboratories 254 . Though more accurate than any combination of the usual CSF biomarkers, RT-QuIC has yet to be directly compared with MRI, which has the disadvantage of being dependent on the reader's skills and expertise.
Network-based biomarkers
In the past few years, network-based neuroimaging techniques, including resting state functional MRI and DTI, have provided research-based biomarkers for neuro degenerative diseases, with promise for the classification of syndromes on the basis of unique structural and functional network alterations (TABLE 1) . For instance, the salience network, which integrates limbic, autonomic and higher-order perceptual functions, and has intimate links to emotional processing, sense of self and rapport with others -critical for social behaviour -shows decreased connectivity and activation in patients with bvFTD compared with healthy controls or patients with AD 7 . In AD, the default mode network (DMN) seems to be especially affected, with AD variants showing decreased connectivity in this network, as well as specific differences in connectivity outside the DMN, such as the visuospatial network in PCA, the language network in lvPPA, and the frontoparietal network in behavioural dysexecutive AD 255 .
Conclusions
Amid the tangled web of neurodegenerative disease, common schemas are emerging. Misfolding of proteins -forming aggregates, disrupting cellular functions, and propagating across functionally and structurally connected vulnerable neuronal networks -seems to lie at the heart of neurodegenerative diseases causing dementia. The pathological cascade can begin years or decades before symptomatic presentation, and clinical deficits eventually arise from irreversible damage within functional networks. Causative genetic factors promote specific proteinopathies, and modifier genes can influence variability in phenotypic presentation.
With disease progression, syndromes converge, and syndromic frontiers efface. In advanced stages of dementia, the footprints of disease extend beyond the initial regions of vulnerability, affecting symptom specificity and diagnostic yield. Therefore, detection of incipient signs and symptoms, or a history that allows early symptoms to be deciphered, is critical for the clinical classification of disease and prediction of the underlying proteinopathy. Nonetheless, despite detailed premortem phenotyping, clinicopathological correlations remain imperfect.
The use of biomarkers has become crucial for in vivo dissection of neurodegenerative syndromes into distinct molecular and structural subtypes, with the ultimate goal of uncovering the factors that are necessary and sufficient to cause neurodegenerative disease. Currently, among the clinically available biomarkers, those for prion disease and AD have the highest predictive values. Patterns of atrophy on structural MRI (FIGS 2, 4) can assist in the diagnosis of other neurodegenerative diseases, with high specificity for certain syndromes and pathologies. Tau PET, functional MRI and DTI, which are currently limited to research, show promise for the detection of mild or prodromal stages of disease.
The incidence of dementia increases with age, but some neurodegenerative diseases -in particular, those with a strong heritable component, such as FTLD -can present early. Taken together with the fact that subclinical structural changes can precede symptomatic disease by decades, vulnerability to dementia might be partially dictated by developmental differences in the brain.
Decades of careful phenotyping and clinical observations, as well as intensive molecular investigations, have culminated in discoveries that have launched a new era in dementia research and patient care. The discovery of causative mutations and related proteinopathies, as well as vulnerable large-scale structurally and functionally related neural networks, is offering molecular windows into the study of disease processes, with opportunities for the development of pathway-specific therapies that could be administered at prodromal or preclinical stages to patients selected on the basis of biomarker positivity.
